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Research Article
Aberrant autophagosome formation occurs upon small
molecule inhibition of ULK1 kinase activity
Maria Zachari , Marianna Longo, Ian G Ganley
Autophagy is a crucial homeostatic mechanism that mediates the
degradation of damaged or excess intracellular components.
Such components are engulfed and sequestered into double
membrane autophagosomes, which deliver their contents to ly-
sosomes for degradation. Autophagy plays a role in numerous
human disorders and its pharmacological targeting by small
molecules offers therapeutic potential. The serine/threonine
kinase ULK1 (and its homologue ULK2) is the most upstream
component of the autophagic machinery and is required for
autophagy initiation. Here, we use the most selective and potent
published ULK1 inhibitors to gain insights into ULK1 kinase
function during autophagy. Treatment with all inhibitors blocked
autophagy but also resulted in the limited formation of initial
autophagosome-like structures, which appeared abnormal in size
and did not traffic to lysosomes. We found that upon ULK1 in-
hibition, phosphatidylinositol-3-phosphate–binding proteins are
still recruited to forming autophagosomes, implying that ULK1
activity is not essential for VPS34 activation. We conclude that the
kinase activity of ULK1 is important in regulating autophagosome
maturation, by the phosphorylation of currently unidentified key
substrates.
DOI 10.26508/lsa.202000815 | Received 16 June 2020 | Revised 19 October
2020 | Accepted 19 October 2020 | Published online 27 October 2020
Introduction
Autophagy is a crucial homeostatic mechanism regulating lysosome-
dependent degradation and recycling of intracellular components.
The most prevalent type of autophagy is calledmacroautophagy and
is the focus of this study. Macroautophagy (simply termed autophagy
from now on) promotes cell survival and cell health, and in general is
considered a disease-preventing mechanism (1, 2). In the context of
cancer, autophagy has a complicated role, as under normal condi-
tions it exhibits a tumour-suppressive role but upon cancer devel-
opmentmultiple cancer cell types rely on autophagy to survivewithin
the tumour microenvironment (3, 4). The process of autophagy in-
volves the de novo generation of a double membrane organelle called
an autophagosome, which grows to engulf cytosolic cargo before
closing to fuse with the lysosome (5). Autophagosome biogenesis is
a complex multistage process and requires the participation of
numerous proteins, which often work in complexes. The multiple
stages of autophagy include initiation, phagophore elongation and
cargo recognition, autophagosome closure, and finally fusion with
lysosomes. A key serine/threonine kinase regulating initiation of
autophagosome formation is Unc-51 like autophagy-activating ki-
nase 1 (ULK1) (and its homologue ULK2). ULK1 is in a constitutive
complex with Autophagy related (ATG) 13 (ATG13), FAK family
interacting protein of 200 kD (FIP200) and ATG101, which together is
known as the ULK1 complex (6, 7, 8, 9). The role of ULK1 during
autophagy has been extensively studied in the context of amino
acid starvation, where it has been shown (in multiple cell lines and
tissues) that in a fed state, ULK1 is suppressed by direct Mechanistic
target of rapamycin complex 1 (mTORC1)-mediated phosphoryla-
tion at multiple sites (including serine 757 in murine or 758 in
human ULK1) (10). Upon amino acid starvation, mTORC1 is inhibited,
resulting in dephosphorylation of ULK1 and subsequent activation
of its catalytic activity. Upon activation, ULK1 is reported to phos-
phorylate multiple downstream autophagy targets (including itself
at threonine 180 and ATG13 at serine 318) to mediate initiation of
autophagy (11, 12). Among these, are components of the second
autophagy initiation complex, the vacuolar protein sorting (VPS) 34
(VPS34) complex. VPS34 is a class-III phosphatidylinositol (PI)-3
kinase and when in complex with Beclin-1, ATG14L, and VPS15
(called the VPS34 complex) produces an autophagy-specific pool of
phosphatidylinositol-3-phosphate (PI3P) that is required for omega-
some formation—an ER-connected platform from which autophago-
somes arise (13, 14, 15, 16). PI3P production recruits PI3P-binding
proteins suchasWD-repeat protein interactingwith Phosphoinositides
(WIPI2) and Zinc Finger FYVE domain-containing protein 1 (DFCP1) (16,
17, 18). The role of these proteins is poorly understood, although one
known function of WIPI2 is to bind and recruit ATG16L1—an essential
protein for autophagosome elongation and lipidation of the auto-
phagosomal membranemicrotubule associated protein 1 light chain 3
(MAP1LC3)—to the autophagosome forming sites (19). The ULK1 com-
plex is upstream of the VPS34 complex and ULK1 kinase activity is
believed to be key for VPS34 complex recruitment and activation (13, 15).
During autophagosome biogenesis, the early autophagy initiating
complexes (ULK1 and VPS34), as well as WIPI2 and DFCP1, are recruited
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transiently to nascent autophagosomes and once they have completed
their roles, they dissociate from it (20, 21). Given the key role of ULK1 in
autophagy initiation and the fact that numerous cancer cells depend on
autophagy for survival, inhibition of ULK1 with small-molecule inhibitors
makes it a promising target for cancer drug discovery (21, 22, 23). Our
laboratory has previously published a study characterising a potent ULK1
inhibitor, MRT68921, which revealed that inhibition of ULK1 in cells blocks
autophagic flux (24). Unexpectedly, instead of complete abolishment of
Figure 1. Stalled autophagosomes upon
inhibition of ULK1 with MRT68921 are
positive for DFCP1 and LC3.
(A) MEF cells expressing GFP-LC3 and mCherry-
DFCP1 were pretreated for 15 min with 1 μM
MRT68921 or DMSO followed by treatment with
EBSS or EBSS and 1 μM MRT69821. The cells were
then immediately subjected to live imaging
using a Nikon Eclipse Ti wide-field microscope.
(B) Representative images of cells are shown at
30 min in and asterisk marks the section
highlighted in panel (B). The movies are
provided as supplementary information (Videos 1
and 2). Scale bar, 10 μm. (A, B) Montage of the
marked areas from themovies shown in (A) from
minutes 22–41. Arrowheads indicate
colocalisation between GFP-LC3 andmCherry-
DFCP1. (B, C) Graphical representation of the
maximum intensity of the mCherry-DFCP1 (red)
and GFP-LC3 (green) puncta indicated with
arrows in (B). (D) Quantitation of the mean time
for which GFP-LC3 and mCherry-DFCP1 signals
colocalised on the same punctate structure
(from n = 4 events, bars represent mean with
SEM). (E) Immunoblot of WT MEF cells treated
with EBSS and 1 μM MRT68921 as indicated. (F)
Quantitation of (E). pS318-ATG13 levels were
normalised to total ATG13 (left) and LC3-II levels
were normalised to Tubulin (right). Data
represent mean of n = 4 ± SEM. Statistical
analysis was performed with two-way ANOVA and
a Tukey’s multiple comparisons test. * = P <
0.05, ** = P < 0.01, **** = P < 0.0001 and ns, not
significant.
Source data are available for this figure.
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autophagosomes upon MRT68921 treatment, we observed that auto-
phagosomes were still forming but they were abnormally bigger in size
and appeared to be stalled (24). These findings suggested that ULK1
kinase activity is regulating later stages of autophagosome formation
as well as initiation. Recently two more structurally distinct small-
molecule ULK1 inhibitors were published (SBI0206965 and ULK-101)
and shown to inhibit ULK1 and autophagy in cells (25, 26). Importantly,
these inhibitors display distinct selectivity profiles and in this study, we
aimed to gain more insights into the kinase function of ULK1 during
autophagy by comparing the common effects of these potent and
selective ULK1 inhibitors.
Results
Inhibition of ULK1 with MRT68921 results in stalled omegasomes
We have previously shown that ULK1 inhibition with MRT68921
results in stalled autophagosome formation and not abolishment,
even though ULK1 is hierarchically the most upstream component
of the autophagic machinery (24). To gain a more comprehensive
comparison of the forming autophagosomes in normal versus
ULK1-inhibited conditions, we performed live imaging using MEF
cells stably expressing the early autophagy protein DFCP1 (tagged
with mCherry at its N-terminus) and LC3 (tagged with GFP at its
N-terminus). For expression levels see Fig S1. DFCP1 marks the
transient omegasome, a structure that acts as a cradle for the
forming autophagosome (16), whereas LC3 is recruited shortly after
DFCP1 and becomes trapped on the inner membrane of the formed
autophagosome until its degradation inside the lysosome. To in-
duce autophagy, we used Earle’s balanced salt solution (EBSS) (an
amino acid starvation medium) and immediately proceeded with
live imaging. Initially, the GFP-LC3 signal appeared diffused in the
cytoplasm but after 15 min of EBSS treatment GFP-LC3 formed
numerous punctate structures, which continued to increase in
number in a time-dependent manner (Fig 1A and B and Video 1).
mCherry-DFCP1 appeared to already form punctate structures from
the beginning, which could be representative of its known local-
isation on Golgi-derived membranes under basal conditions (16).
Nevertheless, a pool of mCherry-DFCP1 was indeed contributing to
newly forming autophagosomes, as suggested by its colocalization
with GFP-LC3. As expected, upon starvation, mCherry-DFCP1 colo-
calised with GFP-LC3–positive puncta for a short period of time
(~3–5 min, Fig 1B–D), followed by dissociation of GFP-LC3, likely as a
fully formed autophagosome, as previously reported (16). Following
dissociation, the autophagosomes remained positive for GFP-LC3
and motile in the cytoplasm (Video 1 and Fig 1B–D). To understand
the effect of ULK1 inhibition on newly forming autophagosomes, we
repeated the experiment in the presence of 1 μΜMRT68921. GFP-LC3
puncta formation took much longer to form following ULK1 inhi-
bition but upon 30 min of treatment, some GFP-LC3-positive auto-
phagosomes started to appear, which colocalised with mCherry-DFCP1
(Fig 1A and Video 2). This suggests that autophagosomes initiate in a
canonical manner even though ULK1 is inhibited. Regardless, GFP-
LC3–positive autophagosomes remained in the omegasome structures
for a long period of time (over 20 min, Fig 1B–D), and instead of
dissociating they increased in size and displayed reduced mobility
(Videos 1 and 2). Inhibition of ULK1 with MRT68921 was confirmed
by Western blot analysis of phospho-ATG13 (at serine 318), a well
characterised substrate of ULK1, and a significant block in LC3-II
flux (Fig 1E and F). Taken together, these data suggest that upon
ULK1 inhibition, autophagosomes are still forming within ome-
gasomes, but they have defects in dissociating from the cradle,
mobilisation, and size regulation. Importantly, the presence of
DFCP1, which requires PI3P for localisation, suggests that VPS34 is
still active despite the fact that ULK1 kinase activity is inhibited
and is examined in more detail below.
Cells expressing kinase-dead ULK1 have phenotypic similarities
with MRT68921-mediated ULK1 inhibition
We have previously shown that cells expressing a MRT68921-resistant
mutant of ULK1 (M92T) are able to rescue the MRT68921-induced
autophagy defect, which strongly suggested the phenotype is spe-
cifically due to ULK1 inhibition and not an off-target effect (24). To
further validate this phenotype, we expressed a kinase-dead form of
ULK1 (K46I, (27)) in double ULK1/2 knockout MEFs (ULK1/2 DKO). As
shown in Fig 2A, in WT MEFs, endogenous ULK1 and LC3 translocate to
numerous small punctate structures, which are partially colocalising
depending on the stage of autophagosome formation. Upon, combi-
nation of EBSS and MRT68921 treatment, enlarged stalled autopha-
gosomes positive for ULK1 and LC3 were observed, as previously
demonstrated (24). In ULK1/2 DKOMEFs that are treated with EBSS and
MRT68921, the appearance of LC3 puncta is vastly diminished, dem-
onstrating that their formation is dependent on ULK1. When we stably
expressed WT Flag-ULK1 in the DKO cells, ULK1 and LC3 again trans-
located to small punctate structures upon EBSS treatment, suggesting
that autophagy is rescued by the presence of WT Flag-ULK1 in the
ULK1/2DKOMEFs (Fig 2A). However, when we expressed K46I Flag-ULK1
in the ULK1/2 DKO MEFs, although we still observed autophagosomes
forming, they were bigger in size and comparable with the ones
appearing upon EBSS +MRT68921 treatment inWTULK1/2MEFs (Fig 2C).
Equal expression of the ULK1 constructs was confirmed by Western
blotting and is shown in Fig 2D. The above data further support that the
MRT68921-induced phenotype is caused specifically by ULK1 kinase
activity inhibition. Moreover, these data show that loss of ULK1 protein
does not have the same phenotype as loss of ULK1 kinase activity. Loss
of ULK1 (and the redundant ULK2) results in dramatic loss of LC3
punctate structures, supporting the notion that ULK1 is indeed the
most upstream autophagy component. In contrast, loss of ULK1 kinase
activity (either by genetic modification or pharmacologically) still re-
sults in recruitment of the autophagic machinery and appearance of
autophagosome-like structures, although these are aberrantly larger
in size and display reduced lysosomal flux (Figs 1E and F, 2, and 3 and
(24)). This is in support of previously published data showing that
catalytically dead ULK1 blocks autophagy (27, 28).
ULK-101 and SBI0206965 treatments result in a phenotype similar
to MRT68921
MRT68921 was the first small-molecule cellular inhibitor of ULK1
reported at the time of its publication. Following this, two other
structurally distinct small molecules, namely, SBI0206965 and ULK-
101 (See Fig S2), were reported by other groups to potently inhibit
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ULK1 and autophagy in cells (25, 26). In the study characterising
SBI0206965, the authors used the CYTO-ID autophagy detection kit
and prolonged treatments to study its effects on autophagic flux.
Although the compound blocked autophagic flux, it was unclear
whether SBI0206965 treatment would also result in stalled auto-
phagosome formation (25). In the study describing ULK-101, the
authors performed immunoblot-based LC3 flux assays to show that
autophagy is inhibited. They also used immunofluorescence im-
aging to monitor DFCP1 and ATG12 structures and observed a re-
duction in their number upon ULK-101 treatment (26). Again though,
it was unclear from this study if ULK-101 also led to stalled auto-
phagic structures. We thus compared the three inhibitors side-by-
side to test whether they displayed phenotypic differences in
autophagosome structures. Initially, we performed immunoblotting
to identify concentrations and time points where ULK1 activity is
sufficiently suppressed and LC3 flux is inhibited, as well as to
confirm the activity status of upstream autophagy-regulating ki-
nases (mTORC1 and AMPK) are not affected. As shown in Fig 3A, both
SBI0206965 and ULK-101 (at 10 and 1 μM, respectively, for 60 min)
significantly inhibited the ULK1-mediated EBSS-induced increase in
pS318-ATG13 levels (quantified in Fig 3B). MRT68921 was also in-
cluded, at 1 μM, where it inhibited ULK1 as expected (Fig 3A and B).
Autophagic flux was also impaired by all of the three ULK1 inhib-
itors, as shown by lipidated LC3 levels (LC3-II) in the presence or
absence of BafA1 (Fig 3A and C) and by flow cytometry of cells
expressing the tandem mCherry-GFP-LC3 reporter ((29) and Fig 3C).
Out of the three inhibitors, MRT68921 appeared to be the most
potent in inhibiting LC3 flux by Western blot, but flux was also
significantly reduced with both SBI0206965 and ULK-101 (Fig 3A–C).
It is worth mentioning here that mTORC1 and AMPK activities (as
monitored by pS757 ULK1 and pS555 levels, respectively) were not
significantly affected upon treatment with MRT68921 and ULK-101,
at least at the concentrations and time points tested (Figs 3A and
S3A and B). A nonsignificant reduction in pS555 ULK1 levels was
observed upon SBI0206965 treatment in Fed conditions, implying
potential AMPK inhibition (Figs 3A and S3B), which has also been
reported elsewhere (30). However, given that AMPK phos-
phorylation of ULK1 (pS555) is dramatically reduced under these
autophagy-inducing conditions, we assume that any AMPK inhib-
itory effects of SBI0206965 will have a negligible impact on ULK1 in
this instance. As with the other inhibitors, mTORC1 activity was
unaffected by SBI0206965 treatment (Figs 3A and S3A). In addition,
we found that treatment of cells with the three inhibitors did not
appreciably disrupt the ULK1 complex itself, as determined by co-IP
of ATG13 and FIP200 with ULK1 (Fig S3C). Because we confirmed that
ULK1 inhibition was achieved with ULK-101 and SBI0206965 in our
hands, we moved on to compare their effects on autophagosome
formation. For this purpose, cells were treated with DMSO or the
ULK1 inhibitors in Fed or EBSS starvation conditions and then co-
stained for ULK1 and LC3, to monitor both early and late
Figure 2. Expression of kinase-dead ULK1 results in
aberrant autophagosomal structures.
(A) WT MEF cells or ULK1/2 double KO (DKO) expressing
Flag-ULK1 WT or Flag-ULK1 K46I (kinase-dead mutant)
were treated with EBSS or EBSS and 2 μΜ MRT68921
for 1 h as indicated. Cells were subsequently fixed and
stained with antibodies against ULK1 (green) and LC3
(red). Arrows mark conventional phagophores,
whereas arrowheads mark abnormal structures. Scale
bar, 10 μm. (B, C) Quantitation of LC3 puncta number (B)
and size (C) in ULK1/2 DKO cells and ULK1/2 DKO cells
expressing Flag-ULK1 WT or Flag-ULK1 K46I, treated with
EBSS for 60 min. Data represent mean of n = 3 ± SEM.
Statistical analysis was performed with one-way
ANOVA and a Tukey’s multiple comparisons test.* = P <
0.05 and ** = P < 0.01. LC3 puncta size was calculated
manually using the “area” tool in NIS Elements. (D)
Immunoblot of lysates from cells used in (A) showing
ULK1 expression levels.
Source data are available for this figure.
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autophagosomal structures. As expected, in the absence of an
autophagy stimulus, the ULK1 inhibitors had little effect on ULK1 and
LC3 puncta formation (Fig S4). However, after amino acid starvation
with EBSS, both ULK1 and LC3 puncta formed in the presence of
inhibitor, although their number was slightly reduced compared with
DMSO-treated controls (Fig 4A and B). In the presence of either of the
ULK1 inhibitors, the autophagosomal structures appeared to be
brighter in intensity and indeed their size was significantly larger
than those formed under control conditions (Fig 4A and B). In ad-
dition, both ULK1 and LC3 were decorating most of the enlarged
autophagosomes (Fig 4A and B), implying stalled early
autophagosomes/phagophores. These data were also confirmed by
co-staining with WIPI2 and GABARAPL1, another early and early/late
autophagosomal marker, respectively (Fig 4C and D). Large LC3
puncta were still apparent after 8 h of EBSS starvationwith inhibitors,
although further work is needed to confirm the actual half-life of
these structures (Fig S5). Thus, the observations initially made with
MRT68921 (Figs 1–3 and (24)) appear common to all three distinct
ULK1 inhibitors, strongly implying that in addition to its upstream
signalling roles, ULK1 catalytic activity is required for autophagosome
maturation.
VPS34 activation can occur following ULK1 inhibition
A key ULK1 substrate is the VPS34 complex (13, 14, 15, 25). However,
the presence of stalled autophagosomal structures upon ULK1
inhibition, which are positive for the PI3P-binding proteins DFCP1
(Fig 2) or WIPI2 (Fig 4), suggests that VPS34 is still able to be ac-
tivated despite ULK1 inhibition. To confirm this, we examined
whether VPS34 inhibition could abolish WIPI2 recruitment to the
ULK1-inhibited structures. We treated cells with EBSS or EBSS in
combination with either MRT68921 or ULK-101 in the presence or
absence of one of the most selective and potent VPS34 inhibitor
available to date, VPS34-IN1 (31). As shown in Fig 5, the presence of
VPS34-IN1 abolished WIPI2 puncta formation in EBSS-only treated
cells as well as those treated in combination with either MRT68921
or ULK-101 (Fig 5A and B). These data suggest that upon ULK1 in-
hibition, VPS34 activity (and concomitant PI3P production) is still
present and is essential to recruit WIPI2 to autophagosome forming
sites. Thus, there are additional factors, independent of ULK1
catalytic activity, that are required for VPS34 activity at the phag-
ophore. In the absence of ULK1 inhibition, VPS34-IN1 also prevented
EBSS-induced ULK1 puncta accumulation, implying a potential
feedback mechanism, although we cannot rule out that puncta still
form but are smaller and harder to distinguish against the high
background staining of the primary antibody used to detect ULK1
(Fig 5A and B). In support of the latter, enlarged ULK1 puncta were
still forming in cells treated with both VPS34-IN1 and MRT68921 or
ULK-101 (although with ULK-101 there appeared fewer in total),
strongly suggesting that ULK1 is upstream of VPS34 (Fig 5A and B
and S6). Similarly, and in support of the requirement for VPS34
activity in LC3 lipidation, stalled LC3-positive autophagosomes
Figure 3. Distinct ULK1 inhibitors impair autophagy.
(A) Immunoblot of lysates fromMEF cells treated with
EBSS, 50 nM BafA1, 1 μM MRT68921, 10 μM SBI0206965,
and 1 μMULK-101 for 1 h as indicated. (B) Quantitation of
pS318-ATG13 levels normalised to total ATG13 (top)
and LC3-II levels normalised to α-Tubulin (bottom).
Data represent mean of n = 4 ± SEM. Statistical analysis
was performed with two-way ANOVA and a Tukey’s
multiple comparisons test. * = P < 0.05, ** = P < 0.01, *** =
P < 0.001, **** = P < 0.0001 and ns, nonsignificant (unless
indicated comparisons of each treatment are with
the relevant DMSO control). (C) Representative flow
cytometry assay of MEF cells expressing mCherry-GFP-
LC3 treated with either DMSO or 50 nM BafA1, or 4 μM
MRT68921, or 20 μMSBI0206965, or 2 μMULK-101 in EBSS
for 4 h as indicated, where a decrease/increase in GFP
and mCherry expression can be observed and
quantified to measure the percent of cells undergoing
autophagy. The number in each panel indicates % of
cells undergoing autophagy. Quantitation of the flow
data is shown on the right and represents mean of
n = 3 ± SEM. Statistical analysis was performed with
one-way ANOVA and a Tukey’s multiple comparisons
test. **** = P < 0.0001.
Source data are available for this figure.
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Figure 4. Distinct ULK1 inhibitors lead to aberrant autophagosomal structures.
(A) MEF cells were pretreated for 15 min with either 2 μM MRT68921, or 1 μM ULK-101, or 5 μM SBI0206965 followed by treatment with EBSS for 1 h in the presence or
absence of the inhibitors at the above concentrations. Cells were fixed and stained for endogenous ULK1 (red), LC3 (green), and DAPI (blue) and imaged with a ZEISS LSM
880 confocal microscope. Scale bar, 10 μm. Boxed area is shown enlarged in zoom panels and dotted line is shown as a line scan below to highlight colocalization and
puncta intensity. (B) Quantitation of indicated data from (A) shown as mean of n = 3 ± SEM. Statistical analysis was performed with a two-way ANOVA and a Tukey’s
multiple comparisons test (or a two-way ANOVA and a Sidak’s multiple comparisons test for puncta size) Note, method of quantitation of LC3 mean size was distinct from
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induced in the presence of MRT68921 were abolished in cells
treated with VPS34-IN1 in combination with MRT68921 (Fig S6). Thus,
although ULK1 may activate the VPS34 complex upon autophagy
stimulation, this is not an absolute requirement for PI3P production
and LC3 lipidation during autophagy stimulation. Taken together,
our data show that not only is ULK1 catalytic activity essential for
starvation-induced autophagy, but that it also plays multiple roles
at distinct stages during the autophagosome maturation. It is not
simply involved in VPS34 activation, but also functions downstream
of this to regulate autophagosome formation and maturation, prior
to release from the omegasome.
Discussion
Specific autophagy inhibitors have both clinical potential for the
treatment of autophagy-dependent cancers but can also act as key
tools to study the function of ULK1 and autophagy in different
contexts (32). So far, the most commonly used autophagy in-
hibitors are Bafilomycin A1 and Chloroquine (or its derivative
hydroxychloroquine), which inhibit lysosomal activity and con-
comitantly autophagy (33, 34, 35, 36). As a result, these compounds
have major effects on the endo-lysosomal pathway and thus do not
allow discrimination between the different autophagy pathways
(microautophagy, macroautophagy and chaperone-mediated auto-
phagy) or lysosomal dysfunction per se. Given that ULK1/2 are
essential for autophagy initiation at both the cell culture and
organismal level (5), ULK1 is a promising target for the development of
autophagy inhibitors (37). Being the most upstream kinase regulating
autophagy, one may expect abolishment of autophagosome structures
upon treatment with ULK1 inhibitors. However, we show that pharma-
cological inhibition of ULK1, with multiple distinct inhibitors, results in
aberrant accumulation of enlarged autophagosomal structures deco-
rated with early markers such as DFCP1 and WIPI2, as well as the later
markers LC3 and GABARAPL1. Importantly, a kinase-dead mutant of ULK1
partially recapitulated this phenotype, further corroborating these
findings. ULK1 can phosphorylate components of the VPS34 complex,
including VPS34 and Beclin-1 and these phosphorylation events are
thought to enhance VPS34 activity to promote autophagosome bio-
genesis (13, 14, 15, 25). Our data show that VPS34 is still able to drive PI3P
formation upon ULK1 inhibition, as shown by recruitment of the PI3P-
binding proteins DFCP1 and WIPI2 to sites of forming autophagosomes.
Therefore, ULK1 may fine-tune VPS34 activity during autophagosome
formation, but our data suggests these ULK1-mediated phosphorylation
events are not an absolute requirement for VPS34 activation during
autophagy stimulation. Indeed, seemingly ULK1-independent VPS34 ac-
tivation mechanisms have been proposed (38).
Interestingly, loss of ULK1 (and its homologue ULK2) does not
result in formation of stalled autophagosomes, but rather a block in
their formation (see Fig 2 and (39, 40)). These important observa-
tions show that the ULK1 complex has both kinase-dependent and
independent functions in autophagy. This is similar to the scenario
observed in yeast, where a kinase-dead mutant of Atg1 (the yeast
homologue of ULK1) resulted in accumulation of autophagy markers
at the pre-autophagosomal structure (PAS) and failure of their
dissociation, which is required for autophagy progression (41, 44). In
the same study, it was highlighted that Atg1 initiates autophagy by
recruiting downstream proteins to the PAS in a kinase-independent
manner; however, its role in the completion of later stages does
depend on its kinase activity (41, 44). These data are similar to our
observations, where inhibition of ULK1 kinase activity does not block
autophagosome formation but results in accumulation of aberrant
early structures. This suggests that the kinase activity–related func-
tions of Atg1 and ULK1 are highly conserved and we speculate that a
key role is to drive autophagosome release from the PAS/
phagophore by phosphorylating, as yet unknown, substrate(s). In
further support for multiple roles, ULK1 has been recently shown to
regulate autophagosome-lysosome fusion by recruiting STX17 in a
PKCα-dependent mechanism (42).
We recently published a study involving two novel ULK1 inhibitor
scaffolds that abolished autophagosome formation (43). However,
these compounds display promiscuous selectivity profiles in contrast
to the inhibitors used here, implying additional kinases may regulate
autophagosome formation (43). This highlights the importance of
selectivity in understanding the mechanisms by which a kinase reg-
ulates a pathway and in avoiding off-target effects that might lead to
artefacts. Our use of three ULK1 inhibitors in this study, with distinct
selectivity profiles, circumvents this problem. Overall, our findings
show that when ULK1 kinase activity is inhibited in cells, autopha-
gosome formation is still primed but fails in later stages, resulting in
aberrant accumulation of stalled autophagosomes. The key sub-
strate(s), the phosphorylation of which is essential for avoiding this
phenotype, are yet to be identified.
Materials and Methods
Chemicals, antibodies and DNA constructs
MRT68921 and VPS34-IN1 were obtained from Medical Research Council
(MRC) Protein Phosphorylation and Ubiquitylation Unit (PPU) Reagents
and Services. ULK-101 was purchased from MedChemExpress EU.
SBI0206965 and Polybrene were from Sigma-Aldrich. Bafilomycin A1 was
purchased from Enzo Life Sciences. The following antibodies were
purchased from CST: ULK1 (8054S), pS757 ULK1 (6888T), pS555 ULK1
(5869S) and LC3 A/B (4108S—used forWestern blot). pS318-ATG13 (NBP2-
19127) was from Novus Biologicals. ATG13 (SAB4200100) was from
Sigma-Aldrich. GABARAPL1 (ab86497) and Vinculin (ab129002)
were from Abcam. FIP200 (17250-1-AP), α-Tubulin (66031-1-IG), and
GAPDH (10494-1-AP) were purchased from Proteintech. The WIPI2
antibody (MCA5780GA) was purchased from Bio-Rad. The LC3 anti-
body (M152-3) used for endogenous immunofluorescence staining
was purchased from MBL. The mCherry antibody (6g6-100) was from
ChromoTek. The ULK1 antibody used for immunoprecipitation (DU
34016) and the DNA constructs used in this study (Flag-ULK1
[DU45617], Flag-ULK1 K46I [DU45618], mCherry-DFCP1 [DU24974],
that used in Fig 2 (see the Materials and Methods section for more detail). (C, D) as in (A, B) but cells were stained for endogenous WIPI2 (green) and GABARAPL1 (red).
Arrowheads mark examples of abnormal WIPI2-GABARAPL1 autophagic structures. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001 and ns, nonsignificant.
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GFP-LC3b [DU40253] and mCherry-GFP-LC3 [DU55696]) were gener-
ated at the MRC PPU Reagents and Services and are available to
purchase online https://mrcppureagents.dundee.ac.uk.
Cell culture and treatments
Immortalised MEF cells ULK1/2 WT or DKO were a gift from Dr Craig
Thompson (Memorial Sloan-Kettering Cancer Center) (39). Cells
were cultured in DMEM supplemented with 10% (vol/vol) FBS
(Sigma-Aldrich), 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/
ml streptomycin (Thermo Fisher Scientific) (fed conditions), in a
humidified incubator, with 5% CO2 at 37°C. For treatments cells were
at ~90% confluency for Western blotting or 60–70% confluency for
imaging on the day of the experiment. For treatments, cells were
pretreated with DMSO or each inhibitor for 15 min (except for Fig 1E,
where pre-treatment was for 60min) followed by further incubation
or starvation for the time points indicated in figure legends. For
starvation cells were washed twice in EBSS, followed by incubation
in EBSS-only or EBSS and 50 nM BafA1 in the presence or absence of
the inhibitors where indicated. The concentrations used for each
compound in the experiments are indicated in figure legends.
Stable cell line generation
To generate the retroviruses carrying the gene of interest, DNA con-
structs in pBABE vectors along with constructs for VSV-G (vesicular
stomatitis virus G protein) and Gag-Pol (both from Takara Bio) were co-
transfected in HEK293-FT cells. 6 μg of the pBABE plasmid, 3.8 μg of Gag-
Pol, and 2.2μg of VSV-Gwere combinedwith 36μl Lipofectamine 2000 in
600 μl Opti-MEM (both from Thermo Fisher Scientific) for 20 min in RT.
For the transfection, the complexes were applied onto a 70% confluent
dish of HEK293-FT cells along with 5ml of Opti-MEMmedium. Opti-MEM
medium was replaced with fresh DMEM culture medium 5 h later. The
next morning, the medium was again replaced with 10 ml fresh culture
medium. 24 h later, the medium containing formed viral particles was
collected and filtered through a 0.45 μm pore size filter and applied to
MEF cells along with 10 μg/ml polybrene to increase the efficiency of
infection. After 24 h, the medium was replaced with fresh medium and
the next day cells were selected either with culture medium containing
2 μg/ml puromycin or with 100 μg/ml hygromycin.
Live imaging
For live cell imaging, MEF ULK1/2 DKO cells expressing Flag-ULK1,
mCherry-DFCP1, and GFP-LC3 were plated onto a four compartment
35-mm glass bottom dish (Ibidi) 24 h before imaging. On the day of
imaging, the cells were washed twice with pre-warmed EBSS fol-
lowed by treatment with EBSS or EBSS and 2 μMMRT68921 and were
immediately transferred to the microscope stage. Two to three
fields were picked and imaged every 1min for a total of 60min using
a Nikon Eclipse Ti wide-field microscope.
Immunofluorescence staining
For immunofluorescence experiments cells were grown on 16-mm
round glass coverslips for 24 h before treatments. Upon treatments,
Figure 5. VPS34 is still active after ULK1 inhibition.
(A) MEF cells were pre-treated for 15 min with either
2 μM MRT68921, or 1 μM VPS34-IN1, or 1 μM ULK-101
followed by treatment with EBSS for 1 h in the presence
or absence of the inhibitors at the above
concentrations. After fixation, the cells were stained for
endogenous ULK1 (red), WIPI2 (green) and DAPI (blue)
and imaged using a Nikon Eclipse Ti wide-field
microscope. Scale bar, 10 μm. (B) Quantitation of data
shown in A representing mean of n = 3 ± SEM. Statistical
analysis was performed with a two-way ANOVA and a
Sidak’s multiple comparisons test. * = P < 0.05, ** = P <
0.01, *** = P < 0.001, **** = P < 0.0001 and ns,
nonsignificant. Comparisons of each treatment are
with the relevant DMSO control.
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the cells were washed in PBS followed by fixation with 3.7% PFA/10
mM Hepes pH 7.0. PFA was quenched in DMEM/10 mM Hepes, pH
7.0/0.02% NaN3 for 20 min in RT. Cells were next permeabilised in
0.2% NP-40/PBS for 10 min and subjected to blocking with 1% BSA/
PBS/0.01% NaN3 (blocking buffer) for 30 min. Primary antibodies
were diluted in blocking buffer (1:200 for ULK1 and LC3, 1:500 for
WIPI2 and GABARAPL1), applied onto coverslips and incubated at
37°C in a humidified chamber for 60 min. Coverslips were then
washed three times (5 min each) with blocking buffer. Secondary
antibodies were applied in 1:500 dilution (in blocking buffer) and
incubated for 30 min at RT, followed by three washes in blocking
buffer (5 min each). Coverslips were thenmounted onto glass slides
with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher
Scientific). Images were taken using a wide-field Nikon Eclipse Ti
wide-field microscope (Figs 1, 2, 5, S5, and S6) or a ZEISS 880
confocal scanning microscope (rest of figures).
Western blotting
For Western blotting cells were washed twice in ice-cold PBS and
were subsequently scraped in lysis buffer (50 mM Hepes, pH 7.4, 150
mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, and protease/
phosphatase inhibitor cocktails as described previously (43)). Ly-
sates were incubated on ice for 20 min, following centrifugation at
20,000g at 4°C. The supernatant was then transferred to a new tube
and lysates were subjected to protein content estimation using Bio-
Rad Protein Assay Dye Reagent Concentrate (Bio-Rad), according to
the manufacturer’s instructions. Samples were prepared in 1× (LDS)
lithium dodecyl sulfate buffer (Thermo Fisher Scientific) before
loading on homemade 8% (or 13% for LC3 blot in Fig 1E) Tris-glycine
gels or 10% Bis-Tris gels (for LC3 blot in Fig 3A only) for electro-
phoresis following standard protocols. Gels were next subjected to
wet transfer onto PVDF membranes. Membranes were blocked in
5% milk in TBS-Tween for 30 min in RT, following washes in TBS-
Tween and primary antibody incubation O/N at 4°C. Antibody di-
lutions were as follows: for ULK1, pS757 ULK1, pS555 ULK1, and FIP200
1:1,000 in 5% BSA/TBS-Tween, for pS318-ATG13 and LC3 1:1,000 in 5%
milk/TBS-Tween, for ATG13 1:5,000 in 5% milk/TBS-Tween, for
mCherry 1:2,000 in 5% BSA/TBS-Tween, for GAPDH 1:10,000 in 5%
BSA/TBS-Tween, for Tubulin 1:40,000 in 5% BSA/TBS-Tween. Upon
primary antibody incubation, membranes were washed three times
in TBS-Tween, followed by secondary antibody (Thermo Fisher
Scientific) incubation for 60 min in RT. Membranes were then
washed three times in TBS-Tween, followed by development on
hypersensitive X-ray films (Fig 1E only) or with a Chemidoc imaging
system (Bio-Rad).
Immunoprecipitation
For co-immunoprecipitation the cells were lysed in lysis buffer and
1 mg of total protein was incubated with 7 μg ULK1 antibody for 60
min at 4°C under rotation. 50 μl slurry of Protein A/G Resin
(Expedeon) were added, followed by incubation for 60 min at 4°C
under rotation. Beads were then washed three times in PBS and
once in lysis buffer and proteins were eluted from beads with 2×
LDS, followed by heating at 95°C for 5 min. Eluates were passed
through a Spin-X column (Sigma-Aldrich) before loading on an 8%
Tris-glycine gel and Western blot analysis.
Flow cytometry
WT MEF cells, stably expressing mcherry-GFP-LC3, were grown on 6 cm
dishes until reaching 70% confluency and treated with either DMSO or
ULK1 inhibitors for 4 h with MRT68921 (4 μM), or ULK1-101 (2 μM), or
SBI0206965 (20 μM) or Bafilomycin A (50 nM) in presence or absence of
EBSS. Cells were harvested for analysis by washing once with PBS,
followed by trypsinisation with Trypsin–EDTA (0.25%) (Thermo Fisher
Scientific). The cells were then fixed in 3.7% PFA/10 mM Hepes, pH 7.0,
for 15 min and finally re-suspended in 0.4 ml of Dulbecco’s PBS
containing 1% FBS into 5 ml Falcon round-bottom polystyrene test
tubes 12 × 75 mm (Thermo Fisher Scientific).
Flow cytometry data were acquired on an LSR Fortessa II with DIVA
software (BD Biosciences). Cells were gated according to their forward-
and side-scatter profiles. 488-nm laser was used to detect GFP in
emission filter 530/30 and 561 nm laser to detect mCherry in emission
filter 610/20. Data were analysed using FlowJo software v10.7.1 (BD
Biosciences). 20–50,000 cells were analysed per condition, with fluo-
rescent detection in green and red channels. Increased autophagywas
determined for individual cells by detecting decreased green versus
red fluorescence, based on gating determined by the green and red
fluorescence of vehicle (DMSO)–treated control cells.
Quantification and statistical analysis
For quantification, a minimum of three independent experiments
were included in the representing graphs as indicated in figure
legends. For Western blot quantification, band densitometry
analysis was performed in ImageJ. Phosphorylated levels of pro-
teins were normalised to the total levels and LC3-II levels were
normalised to loading control, as indicated on the graphs. In Fig 2B,
autophagosome puncta number was quantified manually and
autophagosome size was measured using the “area” tool in NIS
Elements Imaging Software 4.20 (Nikon) and in Fig 4B and D using
Volocity 6.3. Statistical analysis was performed with one- or two-
way ANOVA in GraphPad Prism 8, and an appropriate post-test, as
indicated in figure legends. Line scans were performed by plotting
the intensity profiles of the lines in ImageJ.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000815.
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